These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17223739)

  • 1. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.
    Kallinteris NL; Lu X; Blackwell CE; von Hofe E; Humphreys RE; Xu M
    Expert Opin Biol Ther; 2006 Dec; 6(12):1311-21. PubMed ID: 17223739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
    Xu M; Kallinteris NL; von Hofe E
    Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
    Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
    Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV.
    Kallinteris NL; Lu X; Wu S; Hu H; Li Y; Gulfo JV; Humphreys RE; Xu M
    Vaccine; 2003 Oct; 21(27-30):4128-32. PubMed ID: 14505892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invariant chain-peptide fusion vaccine using HER-2/neu.
    Perez SA; Peoples GE; Papamichail M; Baxevanis CN
    Methods Mol Biol; 2014; 1139():321-36. PubMed ID: 24619690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
    Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
    Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope.
    Kallinteris NL; Wu S; Lu X; Humphreys RE; von Hofe E; Xu M
    J Immunother; 2005; 28(4):352-8. PubMed ID: 16000953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
    Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
    Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
    Dissanayake SK; Tuera N; Ostrand-Rosenberg S
    J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide.
    Humphreys RE; Adams S; Koldzic G; Nedelescu B; von Hofe E; Xu M
    Vaccine; 2000 Jun; 18(24):2693-7. PubMed ID: 10781856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease.
    Kallinteris NL; Powell D; Blackwell CE; Kim M; Lu X; Wu S; Humphreys RE; Xu M; von Hofe E
    Front Biosci; 2006 Jan; 11():46-58. PubMed ID: 16146713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of chimeric vaccines constructed with PEP-1 and Ii-Key linking to a hybrid epitope from heterologous viruses.
    Liu XL; Shan WJ; Xu SS; Zhang JJ; Xu FZ; Xia SL; Dai Y
    Biologicals; 2015 Sep; 43(5):377-82. PubMed ID: 26153399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies.
    Kallinteris NL; Wu S; Lu X; von Hofe E; Humphreys RE; Xu M
    Vaccine; 2005 Mar; 23(17-18):2336-8. PubMed ID: 15755623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
    Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
    J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosting immune response with the invariant chain segments via association with non-peptide binding region of major histocompatibility complex class II molecules.
    Chen F; Meng F; Pan L; Xu F; Liu X; Yu W
    BMC Immunol; 2012 Sep; 13():55. PubMed ID: 23016601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
    Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
    Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases.
    Xu M; Li J; Gulfo JV; Von Hofe E; Humphreys RE
    Scand J Immunol; 2001; 54(1-2):39-44. PubMed ID: 11439146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.